ICG
ALLO icon

InterOcean Capital Group’s Allogene Therapeutics ALLO Stock Holding History

InterOcean Capital Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,000
Closed -$109K – 425
2022
Q1 		$109K Buy
+12,000
New +$125K ﹤0.01% 273

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

InterOcean Capital Group's ALLO Position: Q2 2022 in Review

InterOcean Capital Group sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 12,000 shares — an estimated $109K sold.

InterOcean Capital Group first reported a position in ALLO in Q1 2022 and held it in 1 quarter. The position peaked at $109K in Q1 2022. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

  • InterOcean Capital Group reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
  • InterOcean Capital Group sold 12,000 Allogene Therapeutics shares in Q2 2022, an estimated $109K.
  • InterOcean Capital Group first reported a position in Allogene Therapeutics in Q1 2022 and held it in 1 quarter.
  • InterOcean Capital Group's Allogene Therapeutics position peaked at $109K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on InterOcean Capital Group's 13F filing for Q2 2022, filed 15 Aug 2022.